News | October 13, 2025
Cadila launches allergy relief tablet Dlorfast-M
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Fexofinadine is the most widely used, second-generation antihistamine drug for the treatment of allergy symptoms and hay fever
Subscribe To Our Newsletter & Stay Updated
